查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138302

布鲁氏菌病疫苗全球市场-2022-2029

Global Brucellosis Vaccines Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

市场参与者的努力将在预测期内继续支持市场增长

市场参与者正在采取多项举措，在不发达国家启动宣传计划，以提高人们对牲畜疫苗接种的认识，以维护动物健康和福利。 2018 年 12 月，勃林格殷格翰发起了“最后一英里”计划，通过在难以到达的地区提供动物健康资源，专注于重要的动物健康挑战。该倡议针对绵羊、山羊和牛等反刍动物，併计划扩展到家禽。该公司正在讚助这项由全球家畜兽药联盟 (GALVmed) 支持并由 BMGF 赞助的倡议，以弥合非洲小农在获得、获得和认识动物健康解决方案方面的差距。

2019 年 2 月，粮农组织与渔业和畜牧业部合作发起了牛疫苗接种运动。该运动解决了已导致 3,000 多头牛死亡的有症状炭疽病的爆发。粮农组织将从 2017 年开始扩大规模，以应对日益普遍的动物疾病，目标是拯救约 900 万隻动物。大约 1,000 名以社区为基础的动物卫生工作者接受了培训，通过粮农组织的牲畜应急计划进行例行检查和牲畜疫苗接种。此外，2019 年 9 月，印度政府宣布了一项来自印度马图拉的约 18 亿美元的牲畜疫苗接种计划。该倡议旨在在未来五年内控制牲畜流行病，主要是布鲁氏菌病和口蹄疫（FMD）。

全球布鲁氏菌病疫苗市场报告提供大约 73 个市场数据表、57 个数字和 170 页结构

目录

第一章调查方法及范围

  • 调查方法
  • 市场范围

第 2 章主要趋势和发展

第 3 章执行摘要

  • 按产品类型划分的市场细分
  • 按处理方法划分的市场细分
  • 按诊断划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
    • 约束因素
    • 商机
  • 影响分析

第五章行业分析

  • 波特五力分析
  • 价值链分析
  • 专利分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措

第 7 章品种

  • 羊
  • 牛
  • 山羊

第 8 章治疗

  • 抗生素
  • 疫苗

第 9 章诊断

  • 血清学检测
  • 分子生物学测试
  • 骨髓活检
  • 磁共振成像 (MRI)
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 竞争对手战略分析
  • 市场情况/份额分析
  • 併购分析

第 12 章公司简介

  • AniCon Labor GmbH
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Biogenesis-Bago
  • Calier & Biologicos Laverlam
  • Colorado Serum Company
  • Hester Biosciences Limited
  • Heska Corporation
  • Indian Immunologicals Ltd.
  • Lohmann Animal Health
  • Chengdu Agricultural Machinery Plant
  • Lanzhou Biological Pharmaceutical Plant
  • Inner Mongolia Biological Pharmaceutical Plant
  • Chinese Academy of Agricultural Science

第13章 DataM

简介目录
Product Code: DMHCIT2964

Market Overview

The global brucellosis vaccines market was valued at USD 323.45 million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 4.5% during the forecast period (2022-2029).

The livestock or farm animal's category encompasses cattle, sheep, and goats that are vaccinated to protect against brucellosis diseases. The first dose of this vaccine is given at the age of 4-8 months of calves. It is the most widely used vaccine around the world. The Livestock Vaccine Innovation Fund (LVIF) project collaborates between the J. Craig Venter Institute and the International Livestock Research Institute to promote this vaccine. The LVIF enables improved health of livestock, as farmers' livelihoods depend on livestock. LVIF is an initiative taken by the Bill & Melinda Gates Foundation, Global Affairs Canada, and International Development Research Center (IDRC). It represents a joint investment over five years to reinforce the production, development, and commercialization of innovative vaccines to prevent livestock diseases in sub-Saharan Africa and South and Southeast Asia. The rising prevalence of brucellosis diseases in livestock and the increasing consumption of meat products are some factors that are expected to propel market growth.

Market Dynamics: Initiatives by market players will continue supporting the growth of the market during the forecast period

The market players are taking several initiatives by launching awareness programs in underdeveloped countries to raise awareness about livestock vaccination to maintain animal health and welfare. In December 2018, Boehringer Ingelheim launched the 'LastMile' initiative to focus on crucial animal health challenges by making animal medical resources available in hard-to-reach areas. The initiative targets ruminants, such as sheep, goats, and cattle, and will further expand to poultry. The company started this initiative with support from the Global Alliance for Livestock Veterinary Medicines (GALVmed) and was sponsored by BMGF to bridge gaps in access, availability, and awareness of animal healthcare solutions for smallholder farmers in Africa.

In February 2019, FAO launched a cattle vaccination campaign through collaboration with the Ministry of Fisheries and Livestock. The campaign was intended to address the outbreak of symptomatic anthrax, which has caused the loss of more than 3,000 cattle. The FAO aims to protect nearly 9 million animals from combating increasingly common animal diseases, scaling up from 2017. Around 1,000 community-based animal health workers have been trained and are carrying-out routine check-ups and vaccinating livestock through FAO's Emergency Livestock Response Program. Additionally, the Indian government declared a nearly $1.8 billion livestock vaccination scheme in September 2019 from Mathura, India. This initiative is intended to control livestock diseases, primarily brucellosis and foot and mouth disease (FMD), in the next five years.

Market Segmentation: The cattle segment accounted for the highest share in global brucellosis vaccines market

Cattle contribute a significant share in the brucellosis vaccines market. The market players are continuously offering novel products for the cattle. In September 2018, Boehringer Ingelheim launched a new respiratory vaccine, Bovalto Respi Intranasal, for cattle to protect against viruses Parainfluenza 3 Virus (PI3V) and Bovine Respiratory Syncytial Virus (BRSV). In March 2015, Boehringer Ingelheim launched a new vaccine, Bovela against Bovine Viral Diarrhea (BVD), in Europe for active immunization of cattle against both genotypes of the virus (BVDV-1 and BVDV-2). Besides, Zoetis Inc., in April 2018, expanded its manufacturing and research unit to Suzhou, China, to focus on the vaccines for cattle, pigs, fish, and companion animals.

Based on the treatment, the brucellosis vaccine market has been bifurcated into vaccines and antibiotics. Vaccination plays a considerable role in maintaining the proper health of livestock. The high consumption of meat products globally is further contributing to the livestock vaccine's growth, including the brucellosis vaccines market. Therefore, it contributes a significant share in the development of the brucellosis vaccines market across the globe. Several companies are offering and continuously researching the field of brucellosis vaccine.

Geographical Penetration: North America is the dominating region during the forecast period

North America dominated the global brucellosis vaccines market and is expected to retain its position during the forecast period. The US contributed over XX% to the North American brucellosis vaccines market in 2021. Animal husbandry has been a substantial factor in increasing the demand for vaccination in the region. Biological research is encouraging the development of disease-specific vaccinations for animal welfare.

The Asia Pacific is estimated to grow at a considerable growth rate in the brucellosis vaccines market during the forecast period. This growth can be accredited to the continuous rise in meat consumption and trade in the region, especially in China. China's increasing demand for meat makes it one of the largest markets for animal healthcare products for livestock animals. Such huge stats for animal husbandry are expected to grow the brucellosis vaccines market during the forecast period.

Competitive Landscape:

The Brucellosis vaccines market is fragmented due to multiple companies' availability. Some of the major key players in the market are AbbVie, Inc., AstraZeneca PLC, Bayer AG, BeiGene, CARsgen Therapeutics, CStone Pharmaceuticals Co., Ltd. and GlaxoSmithKline PLC, among others. The key players are adopting various growth strategies, such as acquisitions, product launches, and collaborations, contributing to the growth of the Brucellosis Vaccines market globally. In July 2020, AstraZeneca and Merck & Co., Inc. announced that Lynparza (olaparib) had been approved in the European Union (EU) for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. This approval further provides the company with a significant opportunity to sustain a substantial European pancreatic cancer drugs market position. In June 2020, AbbVie collaborated with Jacobio Pharmaceuticals to develop and commercialize SHP2 inhibitors that act on an important node in cancer and immune cells. In January 2022, AbbVie Announced U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for the treatment of non-small cell lung cancer. In October 2021, US FDA approved Roche's Tecentriq as an adjuvant treatment for people with early non-small cell lung cancer. It is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting.

COVID-19 Impact: Negative impact on the global Brucellosis Vaccines market

The outbreak of COVID-19 has certainly impacted the global brucellosis vaccines market. The lockdown has compelled the veterinaries to close their operations, or even if the vets are open, the public was afraid to visit vets for vaccination during the meantime. Besides, the consumption of meat and dairy products has decreased during the outbreak, which, in turn, has impacted the expansion of livestock across the globe. Therefore, the brucellosis vaccines market is expected to foresee a considerable decline in 2020.

The global brucellosis vaccines market report would provide an access to approximately 73 market data tables, 57 figures and 170 pages

Table of Contents

Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Species
  • 3.2. Market Snippet by Treatment
  • 3.3. Market Snippet by Diagnosis
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Species

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Species Segment
    • 7.1.2. Market attractiveness index, By Species Segment
  • 7.2. Sheep *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Cattle
  • 7.4. Goat

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Treatment Segment
    • 8.1.2. Market attractiveness index, By Treatment Segment
  • 8.2. Antibiotics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Vaccines

9. By Diagnosis

  • 9.1. Introduction
    • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By Diagnosis Segment
    • 9.1.2. Market attractiveness index, By Diagnosis Segment
  • 9.2. Serological Tests*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 9.3. Molecular Techniques
  • 9.4. Bone Marrow Biopsy
  • 9.5. Magnetic Resonance Imaging (MRI)
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key region-specific dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. South America
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.3.6.1. Brazil
      • 10.3.6.2. Argentina
      • 10.3.6.3. Rest of South America
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.4.6.1. Germany
      • 10.4.6.2. U.K.
      • 10.4.6.3. France
      • 10.4.6.4. Spain
      • 10.4.6.5. Italy
      • 10.4.6.6. Rest of Europe
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis

11. Competitive Landscape

  • 11.1. Competitive scenario
  • 11.2. Competitor strategy analysis
  • 11.3. Market positioning/share analysis
  • 11.4. Mergers and acquisitions analysis

12. Company Profiles

  • 12.1. AniCon Labor GmbH*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bayer AG
  • 12.3. Boehringer Ingelheim International GmbH
  • 12.4. Biogenesis-Bago
  • 12.5. Calier & Biologicos Laverlam
  • 12.6. Colorado Serum Company
  • 12.7. Hester Biosciences Limited
  • 12.8. Heska Corporation
  • 12.9. Indian Immunologicals Ltd.
  • 12.10. Lohmann Animal Health
  • 12.11. Chengdu Agricultural Machinery Plant
  • 12.12. Lanzhou Biological Pharmaceutical Plant
  • 12.13. Inner Mongolia Biological Pharmaceutical Plant
  • 12.14. Chinese Academy of Agricultural Science
  • List not Exhaustive*

13. DataM

  • 13.1. Appendix
  • 13.2. About us and services
  • 13.3. Contact us